Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06895031 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Study acronym: STAR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 6, 2026 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Phase: Phase 1/2 to Phase 2v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Mar 27, 2025 to Mar 31, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 27, 2025 to Mar 31, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Trial Details
NCT Number NCT06895031
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov